Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Evogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evogliptin SCHEMBL30866226 | 1.00 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL343846 | 1.00 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL18331680 | 1.00 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL343847 | 1.00 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2496606 | 0.99 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2491978 | 0.99 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2491981 | 0.99 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493817 | 0.98 | DPP4 (0.96) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493812 | 0.98 | DPP4 (0.96) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493525 | 0.96 | DPP4 (0.93) | DPP4KCNH2DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351567-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | DONG A ST CO LTD (KR) | 2017-11-22 | — | — | EP | claimed |
| EP-2142519-B1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | DONG A PHARM CO LTD (KR) | 2014-09-24 | — | — | EP | claimed |
| US-8440669-B2 | Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients | DONG-A PHARMACEUTICAL CO. LTD. (KR) | 2013-05-14 | — | — | US | claimed |
| US-20110201624-A1 | Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2011-08-18 | — | — | US | claimed |
| EP-2351567-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | Dong-A Pharmaceutical Co., Ltd. (KR) | 2011-08-03 | — | — | EP | claimed |
| EP-2351567-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | DONG A ST CO LTD (KR) | 2017-11-22 | — | — | EP | disclosed |
| US-8440669-B2 | Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients | DONG-A PHARMACEUTICAL CO. LTD. (KR) | 2013-05-14 | — | — | US | disclosed |
| US-20110201624-A1 | Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2011-08-18 | — | — | US | disclosed |
| EP-2351567-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | Dong-A Pharmaceutical Co., Ltd. (KR) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201624-A1 | Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients | DPP4, DPP3, DPP7 | DPP4 1/4885KCNH2 3038/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.